Publications by authors named "Brandelyn N Pitcher"

Claim this Profile
L
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
Gita Thanarajasingam, John P Leonard, Thomas E Witzig, Thomas M Habermann, Kristie A Blum, Brandelyn N Pitcher

Lancet Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, Eric D Hsi, Matthew J Maurer, Brandelyn N Pitcher

J Clin Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Maki Tanioka, Cheng Fan, Joel S Parker, Katherine A Hoadley, Zhiyuan Hu, Brandelyn N Pitcher

Clin Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Sonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, Nancy L Bartlett, Nina Wagner-Johnston

Lancet Haematol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance).
Jeanne S Mandelblatt, Jonathan D Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D Tallarico, Brandelyn N Pitcher

Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Lisa A Carey, Donald A Berry, Constance T Cirrincione, William T Barry, Brandelyn N Pitcher

J Clin Oncol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
Minetta C Liu, Brandelyn N Pitcher, Elaine R Mardis, Sherri R Davies, Paula N Friedman

NPJ Breast Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
John P Leonard, Sin-Ho Jung, Jeffrey Johnson, Brandelyn N Pitcher, Nancy L Bartlett

J Clin Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Vicki A Morrison, Sin-Ho Jung, Jeffrey Johnson, Ann LaCasce, Kristie A Blum, Brandelyn N Pitcher

Leuk Lymphoma· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
Juan Du, Sandra Lopez-Verges, Brandelyn N Pitcher, Jeffrey Johnson, Sin-Ho Jung

Cancer Immunol Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).
Heidi D Klepin, Brandelyn N Pitcher, Karla V Ballman, Alice B Kornblith, Arti Hurria

J Oncol Pract· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.
Vanessa B Sheppard, Leigh Anne Faul, George Luta, Jonathan D Clapp, Rachel L Yung, Brandelyn N Pitcher

J Clin Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.
Miguel Martín, Aleix Prat, Alvaro Rodríguez-Lescure, Rosalía Caballero, Mark T W Ebbert, Brandelyn N Pitcher

Breast Cancer Res Treat· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis